Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial - PubMed (original) (raw)
Randomized Controlled Trial
. 2006 Dec;30(12):1729-36.
doi: 10.1038/sj.ijo.0803344. Epub 2006 Apr 18.
Affiliations
- PMID: 16619056
- DOI: 10.1038/sj.ijo.0803344
Randomized Controlled Trial
Oxyntomodulin increases energy expenditure in addition to decreasing energy intake in overweight and obese humans: a randomised controlled trial
K Wynne et al. Int J Obes (Lond). 2006 Dec.
Abstract
Background: Oxyntomodulin has recently been found to decrease body-weight in obese humans and may be a potential anti-obesity therapy.
Objective: To determine whether oxyntomodulin alters energy expenditure, in addition to reducing energy intake, in 'free-living' overweight and obese volunteers.
Design: Randomized double-blind controlled cross-over trial.
Setting: Community and hospital-based.
Participants: Fifteen healthy overweight and obese men and women (age: 23-49 years, BMI: 25.1-39.0 kg/m(2)). All volunteers completed the study protocol.
Interventions: Four-day subcutaneous self-administration of pre-prandial oxyntomodulin, three times daily. Participants were advised to maintain their normal dietary and exercise regimen.
Measurements: (1) Energy expenditure, measured by indirect calorimetry and combined heart rate and movement monitoring; (2) energy intake, measured during a study meal.
Results: Oxyntomodulin administration reduced energy intake at the study meal by 128+/-29 kcal (P=0.0006) or 17.3+/-5.5% (P=0.0071), with no change in meal palatability. Oxyntomodulin did not alter resting energy expenditure; but increased activity-related energy expenditure by 143+/-109 kcal/day or 26.2+/-9.9% (P=0.0221); total energy expenditure by 9.4+/-4.8% (P=0.0454) and physical activity level by 9.5+/-4.6% (P=0.0495). A reduction in body weight of 0.5+/-0.2% was observed during the oxyntomodulin administration period (P=0.0232).
Conclusion: Oxyntomodulin increases energy expenditure while reducing energy intake resulting in negative energy balance. This data supports the role of oxyntomodulin as a potential anti-obesity therapy.
Similar articles
- Subcutaneous oxyntomodulin reduces body weight in overweight and obese subjects: a double-blind, randomized, controlled trial.
Wynne K, Park AJ, Small CJ, Patterson M, Ellis SM, Murphy KG, Wren AM, Frost GS, Meeran K, Ghatei MA, Bloom SR. Wynne K, et al. Diabetes. 2005 Aug;54(8):2390-5. doi: 10.2337/diabetes.54.8.2390. Diabetes. 2005. PMID: 16046306 Clinical Trial. - Exenatide has a pronounced effect on energy intake but not energy expenditure in non-diabetic subjects with obesity: A randomized, double-blind, placebo-controlled trial.
Basolo A, Burkholder J, Osgood K, Graham A, Bundrick S, Frankl J, Piaggi P, Thearle MS, Krakoff J. Basolo A, et al. Metabolism. 2018 Aug;85:116-125. doi: 10.1016/j.metabol.2018.03.017. Epub 2018 Mar 26. Metabolism. 2018. PMID: 29596853 Free PMC article. Clinical Trial. - The effect of topiramate on energy balance in obese men: a 6-month double-blind randomized placebo-controlled study with a 6-month open-label extension.
Tremblay A, Chaput JP, Bérubé-Parent S, Prud'homme D, Leblanc C, Alméras N, Després JP. Tremblay A, et al. Eur J Clin Pharmacol. 2007 Feb;63(2):123-34. doi: 10.1007/s00228-006-0220-1. Epub 2007 Jan 3. Eur J Clin Pharmacol. 2007. PMID: 17200837 Clinical Trial. - The mechanism of action for oxyntomodulin in the regulation of obesity.
Wynne K, Field BC, Bloom SR. Wynne K, et al. Curr Opin Investig Drugs. 2010 Oct;11(10):1151-7. Curr Opin Investig Drugs. 2010. PMID: 20872318 Review. - Impact of estrogens on resting energy expenditure: A systematic review.
Weidlinger S, Winterberger K, Pape J, Weidlinger M, Janka H, von Wolff M, Stute P. Weidlinger S, et al. Obes Rev. 2023 Oct;24(10):e13605. doi: 10.1111/obr.13605. Epub 2023 Aug 6. Obes Rev. 2023. PMID: 37544655 Review.
Cited by
- Obesity pharmacotherapy: current perspectives and future directions.
Misra M. Misra M. Curr Cardiol Rev. 2013 Feb 1;9(1):33-54. doi: 10.2174/157340313805076322. Curr Cardiol Rev. 2013. PMID: 23092275 Free PMC article. Review. - The Gut as an Endocrine Organ: Role in the Regulation of Food Intake and Body Weight.
Melvin A, le Roux CW, Docherty NG. Melvin A, et al. Curr Atheroscler Rep. 2016 Aug;18(8):49. doi: 10.1007/s11883-016-0599-9. Curr Atheroscler Rep. 2016. PMID: 27324637 Review. - Sizing up pharmacotherapy for obesity.
Valentino MA, Terzic A, Waldman SA. Valentino MA, et al. Clin Transl Sci. 2010 Jun;3(3):123-5. doi: 10.1111/j.1752-8062.2010.00191.x. Clin Transl Sci. 2010. PMID: 20590683 Free PMC article. No abstract available. - Newer pharmacological interventions directed at gut hormones for obesity.
Camilleri M, Acosta A. Camilleri M, et al. Br J Pharmacol. 2024 Apr;181(8):1153-1164. doi: 10.1111/bph.16278. Epub 2023 Nov 30. Br J Pharmacol. 2024. PMID: 37917871 Review. - Gut hormone polyagonists for the treatment of type 2 diabetes.
Brandt SJ, Götz A, Tschöp MH, Müller TD. Brandt SJ, et al. Peptides. 2018 Feb;100:190-201. doi: 10.1016/j.peptides.2017.12.021. Peptides. 2018. PMID: 29412819 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical